Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status SAN DIEGO, March 1 ...

In November 2024, Zealand Pharma presented detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial at ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the ...

A swarm of dust storms and tornadoes tore across the southern United States over the weekend, killing at least 39 people and ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

Q4 2024 Earnings Call Transcript March 18, 2025 Operator: Greetings and welcome to the Acurx Pharmaceuticals Fourth Quarter ...

Indeed, based on the Bitcoin Fear and Greed Index, which has been at Fear to Extreme Fear levels for almost a month now, one ...

among other states affected Trump in a statement Sunday evening said they were "actively monitoring" the storm activity and had deployed the National Guard to Arkansas. "My Administration is ready ...

The results of COMP004 build upon previous findings from the Phase 2b trial COMP001, which showed that a single 25mg dose of COMP360 psilocybin was associated with a rapid and highly statistically ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Kurt Gustafson; Chief Financial Officer, Executive Vice President - Finance; OmniAb Inc. Matthew Foehr; President, Chief Executive Officer, Director; OmniAb Inc. Joe ...